Combination therapy in patients with pulmonary arterial hypertension;Medikamentöse kombinationsbehandlung bei patienten mit pulmonal arterieller hypertonie

Deutsche Medizinische Wochenschrift

Volumn 133, Issue 40 SUPPL. 6, 2008, Pages

  Ewert, Ralf ^a   Opitz, C F ^b   Schaper C ^a   Glaser S ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b German Red Cross Hospital   (Germany)

Author keywords

Clinical studies; Combination therapy; Medical treatment; Pulmonary arterial hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; BERAPROST; BOSENTAN; ILOPROST; PLACEBO; PROSTACYCLIN; PROSTANOID; SILDENAFIL; UNIPROST;

ANTIHYPERTENSIVE THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; ECHOCARDIOGRAPHY; HUMAN; LUNG HEMODYNAMICS; PROGNOSIS; PULMONARY HYPERTENSION; SPIROMETRY; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; EXERCISE TEST; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; PIPERAZINES; PROSTAGLANDINS; PURINES; SULFONAMIDES; SULFONES; VASODILATOR AGENTS;

EID: 53849083135     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1091235     Document Type: Conference Paper

References (25)

1. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical Therapy for Pulmonary Arterial Hypertension: Updated ACCP Evidence-Based Clinical Practice Guidelines. Chest 2007; 131: 1917-1928
2. Benza RL, Barst RJ, Galie N et al. Sitaxsentan for the Treatment of Pulmonary Arterial Hypertension: A One Year, Prospective, Open Label, Observation of Outcome and Survival. CHEST, 2008, Juli 14. [Epub ahead of print]
3. Beyer S, Speich R, Fischler M, Maggiorini M, Ulrich S. Long-term experience with oral or inhaled vasodilator combination therapy in patients with pulmonary hypertension. Swiss Med Wkly 2006; 136: 114-118
4. Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol 2008; 51: 1527-1538
5. Dandel M, Lehmkuhl HB, Mulahasanovic S et al. Survival of patients with idiopathic pulmonary arterial hypertension after listing for transplantation: impact of iloprost and bosentan treatment. J Heart Lung Transplant 2007; 26: 898-906
6. Durongpisitkul K, Jakrapanichakul D, Laohaprasitiporn D, Soongswang J, Chanthong P, Nana A. Combination therapy of prostacyclin for pulmonary hypertension in congenital heart disease. J Med Assoc Thai 2005; 88 Suppl 8: S60-S65
7. Ghofrani HA, Rose F, Schermuly RT et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003; 42: 158-164
8. Ghofrani HA, Wiedemann R, Rose F et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002; 136: 515-522
9. Gomberg-Maitland M, McLaughlin V, Gulati M, Rich S. Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. Am J Cardiol 2005; 96: 1334-1336
10. Grünig E, Michelakis E, Vachiery J, Vizza C, Meyer J, Galie N. Acute administration of sildenafil in patients with pulmonary arterial hypertension (PAH) treated with bosentan produced a significant hemodynamic response: results of the COMPASS-1 study. Eur Heart J 2007; 28 (Suppl.): A140
11. Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004; 24: 1007-10
12. Hoeper MM, Leuchte H, Halank M et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006; 28: 691-694
13. Hoeper MM, Taha N, Bekjarova A, Gatzke R, Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 2003; 22: 330-334
14. Humbert M, Barst RJ, Robbins IM et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24: 353-359
15. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J, 2007; 30: 338-344
16. Mathai SC, Girgis RE, Fisher MR et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J 2007; 29: 469-475
17. McLaughlin VV, Oudiz RJ, Frost A et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174: 1257-1263
18. McLaughlin VV, Rubin L, Benza R et al. TRIUMPH I: Efficacy and safety of inhaled treprostinil sodium in patients with pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med 2008; 177 (Suppl.): A965
19. Miwa K, Matsubara T, Uno Y et al. Combination therapy with oral sildenafil and beraprost for pulmonary arterial hypertension associated with CREST syndrome. Int Heart J 2007; 48: 417-422
20. O'Callaghan D, Gaine SP. Combination therapy and new types of agents for pulmonary arterial hypertension. Clin Chest Med 2007; 28: 169-185
21. Olschewski H, Hoeper MM, Borst MM et al. [Diagnosis and therapy of chronic pulmonary hypertension]. Clin Res Cardiol 2007; 96: 301-330
22. Ruiz MJ, Escribano P, Delgado JF et al. Efficacy of sildenafil as a rescue therapy for patients with severe pulmonary arterial hypertension and given long-term treatment with prostanoids: 2-year experience. J Heart Lung Transplant 2006; 25: 1353-1357
23. Seyfarth HJ, Pankau H, Hammerschmidt S, Schauer J, Wirtz H, Winkler J. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy. Chest 2005; 128: 709-713
24. Simonneau G, Rubin L, Galie N et al. Safety and efficacy of sildenafil-epoprostenol combination therapy in patients with pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med 2007; 175 (Suppl.): A300
25. Wilkens H, Guth A, Konig J et al. Effect of Inhaled Iloprost Plus Oral Sildenafil in Patients With Primary Pulmonary Hypertension. Circulation 2001; 104: 1218-1222